Brain natriuretic peptide (BNP) is a cardiac neurohormone of increasing interest over recent years, with research applications expanding at a rapid rate and new data published on a monthly basis. Initially developed as a diagnostic aid for those with acute shortness of breath, clinical applications are now increasing, and this article reviews these clinical applications of BNP and the evidence for effectiveness of the synthetic BNP analogue nesiritide.
Background
The natriuretic peptides are a family of vasoactive vascular neurohormones whose role in cardiovascular homeostasis has been a subject of great interest in recent years. The two members of the family of most interest, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), have been extensively researched, with BNP in particular established as a useful clinical diagnostic and prognostic tool. This review will concentrate on BNP and review the myriad of uses it has taken on in the field of diagnostic chemical pathology, before looking at the role of the synthetic BNP analogue, nesiritide, in the treatment of cardiac failure.
Structure and release
The natriuretic peptides consist of a family of peptides sharing a common amino acid ring, each of which has a different gene responsible for expression. The molecular precursors of ANP and BNP are synthesised predominantly in the myocardium, with different patterns of expression during normality and during disease states, which localise their sites of production predominantly to the atria (ANP) and the ventricle (BNP), though there is some degree of cross-over. 1, 2 Each hormone is produced within cardiac muscle as a pre-prohormone, before cleavage to a prohormone during the intra-cellular post-transcription phase. This prohormone is then cleaved during the secretion process to produce the active hormone, and an inactive pro-terminal peptide component (see Figure 1 ). 3 Both hormones are secreted in response to several factors: G myocardial stretch G increased myocardial pressure G cell hypoxia
The purpose of these stimuli appear to be also multi-fold: G vasorelaxation G diuresis G natriuresis G inhibition of the renin-angiotensin-aldosterone system (RAAS) [1] [2] [3] Both ANP and BNP act via three receptors, the natriuretic peptide receptors (NPR) A, B and C.All appear to be expressed throughout the cardiovascular system, with a particular predilection apparent for the vasculature, lungs and the kidneys. NPR-A and B act via activation of cyclic GMP to modify ion channels in smooth muscle, leading to a reduction in intra-cellular calcium and subsequent vasorelaxation, while also exhibiting direct effects on renal tubules, as well as interacting with the RAAS to modify natriuresis. The combined effects of these actions is, in response to fluid overload, to restore circulatory homeostasis, with NPR-C providing 'the brake' via removal of the active hormone from circulation. 3 The release of BNP in response to a stimulus, such as acute fluid overload, is two-fold, with initial release of stored granules within the first hour followed by rapid up-regulation of mRNA gene expression within the ventricle, producing a second phase of release in the following few hours after the onset of the stimulus. 4 This process produces circulating levels of both BNP and N-Terminal pro-BNP which are far in excess of the normal circulating levels, and their measurement is readily acquired through several commercially available assays. Studies have shown the reliability of each methodology; however, as NT pro-BNP is a more stable molecule, delayed analysis is more accurate.While each method has been validated, it is important to note that assays vary according to calibration and capabilities, making 'normal ranges' assay-specific, rather than uniform across the field. 5, 6 A variety of factors have been shown to affect baseline levels of BNP, with age, gender, renal function, BMI, drugs, and heart rate associated with increases in 'normal' levels. 7, 8 In this review, attention will focus on factors which indicate cardiac disease processes.
Clinical applications of BNP Acute left ventricular failure
When a patient presents to an emergency department with shortness of breath (SOB), physicians are frequently presented with a diagnostic conundrum. Is the SOB secondary to cardiac failure, or pulmonary disease? Clinical signs can be difficult Several papers have demonstrated that in the presence of acute left ventricular failure (LVF), BNP levels increase significantly, usually more than ten-fold, when compared with the normal population.The largest of these studies, the Breathing Not Properly study, looked at 1,586 patients presenting to emergency rooms with acute shortness of breath and found that average BNP levels were significantly raised in both those with systolic (821 pg/ml), and non-systolic (413 pg/ml) heart failure compared with those without a diagnosis of heart failure (34 pg/ml). 9 The ability of BNP to detect abnormal cardiac function was good, with a sensitivity of 90% when the cut-off point was set at 100 pg/ml. These results were similar to work by Lainchbury et al., who provided sensitivities of 80-94% and specificities of 70-89% for ruling out a cardiac cause of shortness of breath. 10 Further evidence from the BASEL study (B-Type Natriuretic peptide for acute shortness of breath evaluation) suggests that the use of BNP reduces the number of patients admitted from emergency rooms to hospital wards, reduces the number of cases requiring intensive care, and reducing the overall costs of hospital treatment. 11 All of these factors were attributed to the ability of BNP to accelerate the diagnostic process, and hence treatment.
It is important to note that these studies have demonstrated that a normal level of BNP, or N-Terminal pro-BNP, is valuable as an adjunct to standard clinical assessment, and not a replacement for it; nor do the authors suggest that BNP is an adequate replacement for echocardiography in patients presenting with new-onset shortness of breath. BNP cannot evaluate the concurrent presence of valvular disease or pulmonary disease, nor can it reliably discriminate any regionality of ventricular impairment or arrhythmia.
BNP and chronic heart failure
Circulating levels of BNP rise acutely during episodes of pulmonary oedema; however, studies have also demonstrated that those with ongoing symptoms of chronic heart failure (CHF) have a chronically raised level of BNP, and that these levels reflect New York Heart Association heart failure scoring. 12 Treatment of chronic symptoms has been shown to reduce BNP in line with an improvement in heart failure status, and this principal can be used to guide out-patient pharmacotherapy. BNP has also been shown to have valuable prognostic capabilities in those with CHF, particularly those in elderly age groups. A raised BNP at the time of admission, discharge and out-patient review predicted adverse events, including re-admission, extended in-patient stay, and death. 13 The prevalence of a raised BNP level in chronic cardiac failure has led to research into the possibility of its utilisation as a screening tool for CHF. of heart failure. 14 Of those, one third, upon full investigation, were diagnosed with heart failure, with BNP providing a valuable rule-out measure in those with a negative diagnosis of CHF (cut-off 22.2 pg/ml, sensitivity 97%, specificity 84%, positive predictive value 70%). The level of cut-off was set much lower than that set for acute pulmonary oedema; as one would expect, the degree of cardiac stretch and pressure overload shows different patterns between disease states.These findings have been replicated in other small studies, and the effectiveness of BNP as a 'gateway' tool to cardiological services is currently under further evaluation. The problem of confounding factors, which can elevate baseline levels of natriuretic peptides may, however, make such a relatively low cut-off less practical in groups such as the elderly and in those with renal failure, LVH or atrial fibrillation.
BNP and diastolic dysfunction
Symptomatic heart failure in the presence of preserved left ventricular function is becoming an increasing problem in the western world. Diastolic dysfunction is increasingly prevalent in the ageing population, and accounts for up to 50% of hospital admissions with heart failure. 15 The use of transmitral Doppler during echocardiography is the current standard method of assessing the presence of diastolic dysfunction. However, this technique has its limitations which are only partially overcome by the use of adjunctive methods such as pulmonary vein flow assessment, or the Valsalva manoeuvre. 16 There is therefore a role for any readily useable diagnostic modality which can assist in the diagnosis of diastolic heart failure.
As has been shown in the Breathing Not Properly study, when presented with a patient complaining of shortness of breath, an acute exacerbation of heart failure was readily diagnosed, whether the patient had preserved systolic function or not; however, the ability to distinguish between systolic and diastolic failure was beyond the scope of the tool. 9 While extremely useful for identifying acute pulmonary oedema, the ability of BNP to identify patients with diastolic dysfunction with or without symptoms of non-acute cardiac failure remains unclear.
Several other papers have suggested a role for BNP in the identification of diastolic dysfunction with or without symptoms of breathlessness. Lubien et al. examined a cohort of patients referred for echocardiography, and found that BNP levels were significantly raised in those with diastolic dysfunction when compared with controls; however, this study has been criticised for insufficient matching of patient controls for age, sex, renal function and LV mass, all factors which could account for differential findings between 'normals' and those with apparent diastolic dysfunction. 17, 18 Other smaller studies have suggested that BNP levels rise in exacerbations of diastolic heart failure. However, the positive and negative predic-tive values vary from study to study, and no definitive consensus has yet been established on the role of BNP in the diagnosis of diastolic dysfunction. 19 Using BNP to screen populations for other forms of cardiac abnormality BNP levels have been demonstrated to correlate with left ventricle (LV) mass as well as LV systolic dysfunction (LVSD). [20] [21] [22] The Framingham Study group screened a population of 3,177 subjects for both these cardiac abnormalities using BNP and echocardiography. BNP levels were shown to be significantly higher in those with LVH and systolic heart failure, although the area under curve of the BNP level was not shown to be significant enough to justify mass population screening for either cardiac abnormality (AUC <0.75 for LVSD/LVH with exception of moderate-to-severe LVSD, which showed AUC of 0.79 for men and 0.85 for women).While the sample size was large, only 70 patients had moderate or severe systolic dysfunction, suggesting that, while the results did not justify mass screening of populations, a more targeted approach may yield benefits. 20 Similar findings regarding the ability of BNP to screen normal populations for LVH were found in similar studies conducted in Portugal and in Japan, again demonstrating raised BNP levels in those with LVH, though the tool was again found to be not sensitive and specific enough to be used in screening of normal populations. 19, 22 The Framingham study also examined a community-based population of people without heart failure, with follow-up extending to 5.2 years. Of 3,346 subjects within the study, 119 patients died and 79 patients suffered first cardiovascular events.Those with elevated levels of baseline BNP showed an increased risk of death, stroke, heart failure and atrial fibrillation, though it was not predictive of new myocardial infarction (MI). These levels were significantly below the accepted 'cutoff' currently used for identifying overt cardiac disease, with values above the 80th centile (20 pg/ml for men and 23.3 pg/ml for women) associated with hazard ratios of 1.62 for death, and 1.76 for a major cardiovascular event. 23 The ability of BNP to act as a widespread screening tool for cardiac disease requires more investigation and, as we further understand the range of confounding variables, this aim does not, at this stage, appear unattainable.
BNP and the risk stratification of acute coronary syndromes
The importance of the cardiac troponins and high sensitivity CRP (hs CRP) has been well established in the prognosis of patients presenting with acute coronary syndromes (ACS). Recent data suggests that BNP may also have additive value over and above these methods in patients presenting with an ACS, irrespective of the degree of LV dysfunction. [24] [25] [26] The TACTICS-TIMI 18 trial demonstrated this in a population of patients presenting to hospital with ACS. Troponin I and hsCRP results obtained from this cohort demonstrated the expected strong prognostic capabilities shown in prior studies, but the addition of BNP was shown to offer further prognostic value, with a greater predictive power for 'death and new cardiac failure', as opposed to troponin I alone, which identified patients at greater risk of 'death and recurrent ischaemic events'. The cut-off point of 80 pg/ml, prospectively defined in this study, demarcated the point where risk begins to rise steeply. These findings were shown to be independent of the presence of the left ventricular systolic dysfunction in these patients, and may reflect a combination of direct hypoxic stimulus to the myocardium, causing release of BNP, in conjunction with degrees of systolic dysfunction which 2D or M-Mode echocardiography are not sensitive enough to detect. Alternatively, this may reflect intermittent periods of regional wall motion abnormalities which resolve before echocardiography. Other suggestions put forward include the interaction of BNP with other neurohormonal factors, which could plausibly lead to a longer lasting elevation of peptide levels. Several other studies have lent support to the concept of BNP levels rising in the presence of ACS, with or without MI, and levels have also been shown to be predictive of infarct size. [26] [27] [28] [29] The impact of interruption to coronary perfusion on BNP levels Early reperfusion has a significant effect on BNP levels post infarct, and this has been demonstrated with angioplasty. 27, 30 The concept of coronary ischaemia causing BNP release was investigated by Tateishi, and also by Kyriakides, who found that the interruption of blood supply to myocardium during revascularisation procedures caused a temporary increase in BNP release, which subsequently returned to baseline within 24 hours. Interestingly, this has not been shown to be the case with ANP. [31] [32] [33] During MI, the duration of interruption of the blood supply also appears to affect the degree of BNP release. Inoue et al. looked at BNP during MI in two groups, one of whom had reperfused after six hours, while the other had not. They demonstrated that the BNP rise reflected the degree of reperfusion, and the rise in levels subsequently predicted the degree of chronic LV impairment, even at the early stage of four hours post-onset of MI.This effect appears to be more than just a postangioplasty phenomenon, with others showing BNP levels to predict the success of CABG after two years of follow-up. 34 BNP messenger RNA upregulation has also been demonstrated in the immediate period following revascularisation. 35 These studies suggest a direct link between the outcome of revascularisation and natriuretic peptide levels.
BNP and the right heart
While in normal subjects there is a relatively low level of production of BNP in the right heart, levels can rise significantly in disease states. BNP has been shown to be elevated in patients with right heart failure, pulmonary embolus, primary pulmonary hypertension and congenital heart disease causing right ventricular overload. [36] [37] [38] [39] [40] [41] [42] Potential uses of this are still being evaluated, with the use of BNP in the timing of interventions in the field of paediatric cardiology a potentially attractive application; particularly in those with septal defects and other abnormal vascular communications which predispose to a gradual elevation in right heart pressures.
BNP as a treatment -Nesiritide
While BNP elevation is associated with poor outcomes, it is important to realise that BNP appears to represent the human body's attempt at treatment of the underlying cause.A high level is not a bad thing in itself; rather, it reflects an attempt at correction of a deleterious underlying process.
The synthetic recombinant BNP analogue, nesiritide, has been manufactured as an intravenous agent for use in patients with heart failure, and has been shown to reduce pulmonary capillary wedge pressure and peripheral arterial resistance within hours of the onset of its infusion. This reduction in pre-load and afterload comes without any direct affect on inotropic or chronotropic properties of the heart, making it a potentially desirable 'off-loader' in situations for which intravenous nitrates are currently used. 43 Of further benefit, in a direct comparison with dobutamine, nesiritide was found to be superior in the management of decompensated heart failure in terms of lower levels of life-threatening arrhythmia and survival, though numbers were small. 42 The principal undesirable action of nesiritide is that of hypotension, and therefore is contra-indicated in those with significant hypotension. However, as with GTN, this is dose-dependent and mostly resolves after a short period without infusion; otherwise there are few known serious side effects. While data from the VMAC (Vasodilatation in the management of acute CHF) study has shown nesiritide to have at least equivalent shortterm outcomes to nitrates in those with acute decompensated heart failure, six-month follow-up showed no significant difference in morbidity or mortality and, with the current prohibitive cost of nesiritide, its first line use appears difficult to justify with the current evidence base.
Summary
BNP is a cardiac neurohormone with beneficial actions on fluid homeostasis. Release appears to be in response to ventricular stretch, pressure overload and ischaemic insult, with raised levels resulting in vasorelaxation, natriuresis and diuresis. Levels can be used to confirm a diagnosis of acute heart failure, to assist in the diagnosis and treatment of chronic heart failure, and in the assessment of ACS. Several factors cause variation in baseline levels, which at the moment make it an impractical tool for the screening of unselected populations for cardiac disease; however, the use of BNP can be justified as part of the general assessment of the majority of cardiac patients.The synthetic analogue nesiritide may prove to be an exciting new treatment in the field of cardiac critical care. However, more research is required before it can be considered as routine therapy in those with decompensated heart failure. 
